Archford Capital Strategies LLC lowered its stake in shares of CVS Health Corp (NYSE:CVS) by 16.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 15,863 shares of the pharmacy operator’s stock after selling 3,173 shares during the quarter. Archford Capital Strategies LLC’s holdings in CVS Health were worth $1,290,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC grew its position in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC grew its position in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 991 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after acquiring an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in CVS Health in the 2nd quarter valued at $119,000. Finally, Captrust Financial Advisors bought a new position in CVS Health in the 2nd quarter valued at $155,000. 80.81% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CVS Health Corp (CVS) opened at $70.11 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.52 and a current ratio of 1.02. The firm has a market capitalization of $71,020.00, a price-to-earnings ratio of 11.88, a P/E/G ratio of 1.16 and a beta of 0.92. CVS Health Corp has a 12 month low of $66.45 and a 12 month high of $84.00.
CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.04. The firm had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.71 EPS. analysts anticipate that CVS Health Corp will post 6.47 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 33.90%.
Several equities analysts have commented on CVS shares. Jefferies Group set a $86.00 price objective on CVS Health and gave the company a “hold” rating in a research report on Wednesday, October 18th. Mizuho set a $90.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and issued a $77.00 price objective on shares of CVS Health in a research report on Friday, October 27th. Loop Capital reaffirmed a “hold” rating on shares of CVS Health in a research report on Friday, October 27th. Finally, Cowen set a $86.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. CVS Health currently has a consensus rating of “Buy” and a consensus target price of $87.82.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.61% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Archford Capital Strategies LLC Has $1.29 Million Stake in CVS Health Corp (CVS)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/archford-capital-strategies-llc-has-1-29-million-stake-in-cvs-health-corp-cvs.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.